Product Center
Ab&B Bio-Tech Co., Ltd. JS's Tetravalent Influenza Virus Subunit Vaccine Approved for Launch
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-18
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed full-dose adjuvant-free tetravalent influenza virus subunit vaccine (Huier Kangxin®) has been approved for marketing by the National Medical Products Administration (NMPA), marking China's first approved tetravalent influenza virus subunit vaccine.
Ab&B Bio-Tech Co., Ltd. JS's Tetravalent Influenza Virus Subunit Vaccine Approved for Launch
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed full-dose adjuvant-free tetravalent influenza virus subunit vaccine (Huier Kangxin®) has been approved for marketing by the National Medical Products Administration (NMPA), marking China's first approved tetravalent influenza virus subunit vaccine.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-18 11:00
- Views:
Huier Kangxin® extracts only effective antigens, featuring high purity, low vaccination side effects, excellent safety profile, and comprehensive protection, and is classified as a Category 1 preventive biological product. The clinical trial results all reached the primary endpoints and were published in the international authoritative journal Vaccine, and were cited by the Technical Guidelines for Influenza Vaccination in China (2021-2022) and Technical Guidelines for Influenza Vaccination in China (2022-2023) respectively.
Clinical results show that Huier Kangxin® is a safe and effective influenza vaccine that can provide broader and more robust protection against seasonal influenza viruses. The vaccine is expected to serve as an important component of influenza prevention strategies and contribute to global influenza prevention and control efforts.
Ab&B Bio-Tech Co., Ltd. JS is committed to the research and development, regulatory submission, industrial production, and commercialization of innovative human vaccines. The company adheres to international standards and conducts independent innovation research. Currently, the quadrivalent influenza virus subunit vaccine (for 6-35 months old), quadrivalent influenza virus subunit vaccine (for 3 years old and above), 23-valent pneumococcal polysaccharide vaccine, and freeze-dried human rabies vaccine (human diploid cell) have all obtained clinical trial approvals, with clinical trials and New Drug Applications (NDA) progressing in an orderly manner.
In recent years, the company has continued to increase R&D investment. The Shanghai/Taizhou R&D Center and pilot test platform are advancing multiple pipelines including viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccines simultaneously.
Avoiding imitation, focusing on international trends, and developing innovative vaccines are the guiding principles of Ab&B Bio-Tech Co., Ltd. JS. "Caring for life and protecting health" is the mission of Ab&B Bio-Tech Co., Ltd. JS! The company will uphold the spirit of innovation, pragmatism, self-discipline, integrity, and persistent dedication, striving to make global innovative vaccines accessible in China and deliver high-quality Chinese vaccines to the world!
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
